Med24
clinical-research 28. 10. 2026 • 2 min read • ClinicalTrials.gov (Lincoln University College)

Effectiveness of an Empathy and Communication Training Program on Nurse-Reported Therapeutic Engagement Among Psychiatric Nurse Specialists in Saudi Arabia: A Two-Site Quasi-Experimental Study With an Explanatory Sequential Mixed-Methods Design

This study tests whether a five-day Empathy and Communication Training Program (ECTP) helps psychiatric nurse specialists in Saudi Arabia engage better with their patients. Good relationships between nurses and patients are central to mental health care, but structured training in empathy and communication is limited...

Anemia is an independent predictor of increased overall mortality in older adults – results from the PolSenior study

This study investigated whether a five-day Empathy and Communication Training Program (ECTP) improves therapeutic engagement among psychiatric nurse specialists in Saudi Arabia. The research aimed to determine if structured training in empathy and communication would positively impact patient relationships within Saudi psychiatric hospitals. Good relationships between nurses and patients are central to mental health care, but structured training in empathy and communication is limited in Saudi psychiatric hospitals.

ECTP Program Details

The ECTP, a five-day, face-to-face program, covered empathy and communication, the work environment, language and cultural barriers, and emotional preparedness. Sessions utilized short lectures, role-play, case discussions, and reflective group activities. The program was delivered by nurse educators and psychiatric nurse trainers with experience in mental health education. The intervention took place at the Eradah Complex for Mental Health in Dammam and the Eradah Hospital for Mental Health in Madinah. Nurses at each site were assigned to the training program based on their institution.

Sponsored content

Methodological Approach

Participants completed a 15-item questionnaire assessing therapeutic engagement before and after the training. The questionnaire was adapted from the Therapeutic Engagement Questionnaire. Following the program, a subset of intervention group nurses participated in semi-structured interviews to explore their experiences and remaining barriers. The interviews continued until thematic saturation was achieved. A minimum of 64 participants were planned for each group, with adjustments made for attrition and finite populations.

Original Scientific Source
ClinicalTrials.gov (Lincoln University College)
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Evaluation of the Espansione Equinox System Safety & Effectiveness for the Treatment of Meibomian Gland Dysfunction: A Prospective, Multicenter, Randomized Controlled Investigation
clinical-research

Evaluation of the Espansione Equinox System Safety & Effectiveness for the Treatment of Meibomian Gland Dysfunction: A Prospective, Multicenter, Randomized Controlled Investigation

The purpose of this study is to demonstrate the non-inferiority of the Equinox System with respect to iLux 2020. Approximately 120 participants are expected to take part in the research trial at a minimum of three (3) and up to five (5) sites across the United States. The expected duration of the study will be six (6)...

16. 11. 2026 Read article →
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant C
clinical-research

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant C

This randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

16. 11. 2026 Read article →
Comparison of Clinical Outcomes Associated With Different Transcranial Magnetic Stimulation Protocols Combined With Botulinum Toxin-A Injection in Post-Stroke Upper Limb Spasticity
clinical-research

Comparison of Clinical Outcomes Associated With Different Transcranial Magnetic Stimulation Protocols Combined With Botulinum Toxin-A Injection in Post-Stroke Upper Limb Spasticity

Post-stroke upper limb spasticity is an important condition that negatively affects motor recovery, upper limb functions, and activities of daily living. Multimodal treatment approaches are recommended in the management of spasticity. In recent years, the effects of transcranial magnetic stimulation (TMS) on upper...

10. 11. 2026 Read article →
A Phase I/II Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Quizartinib in Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
clinical-research

A Phase I/II Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Quizartinib in Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

This phase I/II trial studies the side effects and best dose of CPX-351 in combination with quizartinib for the treatment of acute myeloid leukemia and high risk myelodysplastic syndrome. CPX-351, composed of chemotherapy drugs daunorubicin and cytarabine, works in different ways to stop the growth of cancer cells,...

10. 11. 2026 Read article →
Advertisement